Targeted protein functionalization using His-tags

Bioconjugate Chemistry
Gavin D MeredithNancy L Allbritton

Abstract

With the impressive growth in gene sequence data that has become available, recombinant proteins represent an increasingly vast source of molecular components, with unique functional and structural properties, for use in biotechnological applications and devices. To facilitate the use, manipulation, and integration of such molecules into devices, a controllable method for their chemical modification was developed. In this approach, a trifunctional labeling reagent first recognizes and binds a His-tag on the target protein's surface. After binding, a photoreactive group on the trifunctional molecule is triggered to create a covalent linkage between the reagent and the target protein. The third moiety on the labeling reagent can be varied to bring unique chemical functionality to the target protein. This approach provides: (1) specificity in that only His-tagged targets are modified, (2) regio-specific control in that the target is modified proximal to the His-tag, the position of which can be varied, and (3) stoichiometric control in that the number modifications is limited by the binding capacity of the His-tag. Two such labeling reagents were designed, synthesized, and used to modify both N- and C-terminally His-tagged version...Continue Reading

References

Feb 21, 1996·Journal of the National Cancer Institute·R G Melton, R F Sherwood
Jun 26, 1998·Journal of Photochemistry and Photobiology. B, Biology·F Boscá, M A Miranda
Mar 6, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J Turková
Mar 14, 2001·Journal of Biochemical and Biophysical Methods·M K WalshB C Weimer
Oct 19, 2002·Angewandte Chemie·Christof M Niemeyer, Michael Adler
Dec 7, 2002·Nature Biotechnology·Antje KepplerKai Johnsson
Jun 20, 2003·Journal of Proteome Research·Andrew V OleinikovKilian Dill
Jun 26, 2003·Journal of the American Chemical Society·Maik KindermannKai Johnsson

❮ Previous
Next ❯

Citations

Sep 11, 2009·Journal of the American Chemical Society·Tracy M BloisJames U Bowie
Sep 28, 2006·Chemical Communications : Chem Comm·Kei HondaItaru Hamachi
Aug 25, 2007·Nanomedicine·Steven S Smith
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Christina T Hauser, Roger Y Tsien
Oct 25, 2006·Applied Microbiology and Biotechnology·Pall ThordarsonKelly Velonia
Nov 13, 2007·Journal of Biomedical Optics·Zhen-Dan ShiGary L Griffiths
Feb 26, 2015·Proceedings of the National Academy of Sciences of the United States of America·Yau-Tsz LaiHongzhe Sun
Aug 16, 2016·Bioinorganic Chemistry and Applications·Dongxin Zhao, Zhongxian Huang
Dec 17, 2016·Chemical Reviews·György DormánGlenn D Prestwich
Apr 27, 2017·Nanoscale·H BelkahlaO Micheau
Feb 6, 2007·Colloids and Surfaces. B, Biointerfaces·Sylvia DaunertSapna Deo
Mar 11, 2016·Molecular BioSystems·Jonathan LotzeAnnette G Beck-Sickinger
May 8, 2008·Chembiochem : a European Journal of Chemical Biology·Martin HintersteinerManfred Auer
Jan 22, 2010·Angewandte Chemie·Christof M Niemeyer
Jun 7, 2013·Angewandte Chemie·Seraphine V Wegner, Joachim P Spatz
Feb 28, 2019·Chemical Science·Karolina PeciakSteve Brocchini
Jul 8, 2017·Metallomics : Integrated Biometal Science·Javier Jiménez-Lamana, Joanna Szpunar
Feb 14, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Ailun ChaoHongzhe Sun
Apr 2, 2008·Journal of the American Chemical Society·Kalina PenevaKlaus Müllen
Dec 7, 2007·Journal of the American Chemical Society·Hiroshi NonakaItaru Hamachi
Oct 18, 2008·Bioconjugate Chemistry·A M GouldingS K Deo
Mar 10, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Makan KhoshnejadVladimir R Muzykantov
Feb 5, 2019·Chemical Reviews·Mikael Madsen, Kurt V Gothelf
Aug 10, 2018·Bioconjugate Chemistry·Michael R MortensenKurt V Gothelf
May 4, 2018·Biomacromolecules·Yanjing Wang, Chi Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.